



## Unusual Bullish Trade in DBV Tech for Allergy Solution

Ticker/Price: DBVT (\$9.50)

### Analysis:

**DBV Tech (DBVT)** a coiled chart set-up and a name with no notable open interest today seeing 1800 November \$10 calls open for \$1.80. Short interest at 9.5% of the float has risen to a three year high. The \$700M clinical-stage biopharmaceutical saw peer Aimmune (AIMT) see its peanut allergy drug as the first FDA-approved. DBVT also has a Phase 3 Peanut Allergy candidate and a Phase 2 for Milk. HC Wainwright out recently saying DBVT still has the edge with less safety concern for Viaskin, and has a \$25 target on shares. Goldman started shares Buy with a \$14 target in June, catalysts include Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Perceptive Advisors, Deerfield, and Boxer Capital among top buyers in DBVT in Q2.

### Hawk Vision:



**Hawk's Perspective:** DBVT is interesting versus the recent reversal low, clearly an event-driven name but looks like a potential emerging winner in this niche.

**Confidence Ranking:** \$\$